TD Cowen Maintains Buy on Biogen, Lowers Price Target to $275
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Phil Nadeau maintains a Buy rating on Biogen but lowers the price target from $300 to $275.
October 31, 2024 | 5:04 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
TD Cowen has maintained a Buy rating on Biogen but reduced the price target from $300 to $275, indicating a slightly less optimistic outlook.
The maintenance of a Buy rating suggests continued confidence in Biogen's prospects, but the lowered price target indicates some concerns or adjustments in expectations. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100